Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Rekovelle Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
Historical growth was driven by a rise in infertility rates, the expansion of assisted reproductive technology clinics, a trend of increasing maternal age, enhanced availability of fertility medications, and the clinical validation of recombinant hormone therapies.
Anticipated expansion during the forecast period is primarily driven by a heightened demand for in-vitro fertilization (IVF) treatments, an escalating preference for tailored fertility solutions, the broadening scope of fertility tourism, increasing capital allocation towards reproductive health, and ongoing advancements in hormonal stimulation therapies.
Significant trends expected throughout the forecast period involve a wider embrace of individualized fertility solutions, an uptick in the application of recombinant gonadotropins, a sharpened emphasis on customized ovarian stimulation regimens, an increase in the overall volume of IVF procedures, and improved accuracy in hormone administration.
Get A Free Sample Report With In-Depth Market Insights:
Rekovelle Market Development Factors: What’s Supporting Demand?
The Rekovelle market is expected to grow due to the increasing prevalence of infertility rates. Infertility rates denote the proportion of couples or individuals within a specific population who are unable to conceive after approximately one year of regular, unprotected sexual intercourse. The rising incidence of infertility is fueled by factors such as delayed childbearing, changes in lifestyle, exposure to environmental toxins, and various medical conditions, leading to a greater need for fertility treatments. Rekovelle helps mitigate infertility rates by improving ovarian response and enhancing the success of assisted reproductive technologies like IVF, thereby increasing the chances of successful fertilization and pregnancy. For instance, in April 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 17.5% of the global adult population, or about 1 in 6 individuals, face infertility. Therefore, the increasing prevalence of infertility contributes to the growth of the Rekovelle market. The Rekovelle market’s growth is anticipated to be propelled by the rising prevalence of genetic conditions. Genetic conditions are disorders resulting from abnormalities in an individual’s DNA, including mutations, deletions, or duplications. The increase in genetic conditions is attributed to advanced parental age, which heightens the risk of DNA mutations in eggs and sperm. Rekovelle supports patients with fertility challenges linked to genetic factors by stimulating ovarian follicle development for effective IVF treatment. For instance, in March 2024, according to the Gene People, a UK-based registered charity, genetic conditions affect an estimated 1 in 25 children, impacting over 2.4 million children and adults in the UK. Therefore, the increasing prevalence of genetic conditions is driving the growth of the Rekovelle market.
Rekovelle Market Segment Breakdown: Which Categories Lead On Revenue?
The rekovelle market covered in this report is segmented –
1) By Indication: Controlled Ovarian Stimulation, Polycystic Ovary Syndrome
2) By Distribution Channel: Hospitals, Clinics, Pharmacies
3) By End User: Pediatric, Adult, Geriatric
Rekovelle Market Transformation Trends: What Innovations Are Driving Change?
Leading companies within the Rekovelle market are concentrating on developing novel solutions, such as personalized ovarian stimulation, to address the increasing need for more effective and safer fertility treatments. This personalized approach customizes the therapy, specifically the drug dosage, for each individual based on their unique characteristics, like body weight and anti Müllerian hormone levels, rather than applying a standard dose for everyone. In March 2023, Ferring Pharmaceuticals A/S, a Switzerland-based pharmaceutical company, revealed data from the PROFILE study, which represented the inaugural prospective, real-world investigation of Rekovelle (follitropin delta). The results indicated that approximately 74% of participants retrieved between 4 and 19 oocytes, and the ongoing pregnancy rates corresponded with those observed in previous Phase 3 trials. An individualized dosing algorithm, formulated based on body weight and AMH, was utilized in 95% of the cases. These findings affirm Rekovelle’s efficacy and safety within a real-world, personalized ovarian stimulation context.
Rekovelle Market Leading Players And Competitive Positioning
Major companies operating in the rekovelle market are Ferring Pharmaceuticals A/S
View The Full Rekovelle Market Report:
Rekovelle Market Leading Geography: Which Region Contributes The Most Revenue?
Europe was the largest region in the rekovelle market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rekovelle market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
